Monday, April 1, 2013

Indian Supreme Court Rejects Novartis plea for Glivec patent

In a bold move, India's top court has dismissed Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.

India's domestic drugs market is the 14th largest globally, but with annual growth of 13-14 percent and the world's second biggest population, it has massive potential at a time when traditional developed markets have slowed down.

The Indian Supreme Court's landmark ruling is likely to affect several other companies and their branded medicines.

Read more about it at: Reuters
Follow us on Facebook


Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More

Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Web Hosting Bluehost